Foghorn Therapeutics Inc. (FHTX) vs Protalix BioTherapeutics, Inc. (PLX)
Foghorn Therapeutics Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Foghorn Therapeutics Inc. and Protalix BioTherapeutics, Inc. are of similar size ($221.6M and $213.8M). Foghorn Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.3×. Foghorn Therapeutics Inc. grew revenue faster over the last twelve months: 52.0% against 30.1%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs −175.8%) and the higher return on invested capital (48.5% vs 0.00%). Across the 16 metrics below, Protalix BioTherapeutics, Inc. leads on 9 and Foghorn Therapeutics Inc. on 7.
Valuation
Profitability
| Metric | FHTX | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 69.20% | 65.16% |
| Operating margin | (198.04%) | 28.89% | 0.00% |
| Net margin | (175.78%) | 23.50% | 0.00% |
| Free cash flow margin | (229.49%) | 9.51% | 0.00% |
| Return on equity | 81.90% | 31.23% | (57.72%) |
| Return on assets | (30.06%) | 20.07% | (49.22%) |
| Return on invested capital | 0.00% | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack